Acute Myeloid Leukemia Clinical Trials
Last reviewed: November 17, 2026
Start with whether AML is newly diagnosed, relapsed or refractory; list exact prior medicines, transplant history and molecular results. Older age alone does not determine fitness for intensive treatment. Trial age limits and physician-assessed fitness are separate requirements.
Answer a few questions to find clinical trials matched to your specific Acute Myeloid Leukemia situation.
Results usually take about 15 minutes after you submit. Email is optional. No sign-up.
Find matching trials →
Current Clinical Trial Landscape
Active research areas in 2026:
- Menin inhibitors for NPM1-mutated and KMT2A-rearranged AML: revumenib, ziftomenib, bleximenib — all in Phase 3 in 2026 (covers ~30% of adult AML, NPM1 being the single most common AML mutation)
- Venetoclax-based combinations: backbone of both intensive induction and non-intensive (HMA + venetoclax) regimens; multiple Phase 3 maintenance and conditioning trials
- FLT3 inhibitors: gilteritinib, quizartinib, HEC73543, next-gen agents in frontline, post-transplant maintenance — and (new in 2026) expansion into FLT3-ITD negative AML
- IDH1/2 inhibitors: ivosidenib, enasidenib, dual IDH1/2 inhibitor HMPL-306 — combinations with HMA ± venetoclax
- Transplant optimization and cellular therapy: PT-Cy GVHD prophylaxis, MRD-guided conditioning, mocravimod, venetoclax-augmented conditioning, CAR-T
Already approved: Venetoclax + azacitidine, all-oral decitabine/cedazuridine (Inqovi) + venetoclax for newly diagnosed AML in patients ≥75 or unfit for intensive chemotherapy (FDA May 13, 2026; CR 41.6% in ASTX727-07), midostaurin/gilteritinib/quizartinib (FLT3), ivosidenib (IDH1), enasidenib (IDH2), menin inhibitors revumenib (R/R KMT2A-rearranged acute leukemia, Nov 2024; R/R NPM1-mutated AML, Oct 2025) and ziftomenib (Komzifti, R/R NPM1-mutated AML, Nov 2025), gemtuzumab ozogamicin (CD33), CPX-351.
Post-ASCO 2026 update (June 13): The menin inhibitor class is the AML headline of 2026. Revumenib (KMT2A-rearranged R/R approval Nov 2024) is being tested in Phase 3 frontline studies including
NCT07211958 (with 7+3) and
NCT06652438 (with HMA + venetoclax). Ziftomenib (
NCT07007312) and bleximenib (
NCT06852222,
NCT07223814) are advancing in parallel.
NPM1-mutated patients can discuss menin inhibitor studies with their treating team; mutation positivity alone does not establish eligibility. Separately, the FLT3 inhibitor class is expanding into
FLT3-ITD negative disease with
NCT06578247 (quizartinib + chemo; enrollment complete, awaiting readout).
Approved treatment versus research: US revumenib approval for susceptible NPM1-mutated relapsed/refractory AML applies from age 1 when no satisfactory alternative exists; ziftomenib applies to adults in that setting. Revumenib also has a separate KMT2A-translocation relapsed/refractory acute leukemia indication. These approvals do not establish eligibility for a frontline combination trial. Breakthrough designation is not approval.
Finding AML trials for NPM1 or KMT2A results
Start with the exact wording of your molecular report, then check the study’s treatment setting and prior-treatment requirements. A mutation result alone does not establish eligibility. Use the sections below to find study examples to discuss with your hematology team.
| What you know | Where to start on this page |
| Your report lists an NPM1 mutation. | Read NPM1-Mutated / KMT2A-Rearranged — Menin Inhibitors, then check which molecular result and treatment setting each study requires. |
| Your report lists a KMT2A rearrangement. | Start with the same menin-inhibitor section, but check the exact cohort requirements. Do not assume that every result mentioning KMT2A matches a study requiring a rearrangement. |
| You have another molecular result, or are unsure what the report means. | Look at Selected Trials by Molecular Subtype, including the FLT3, IDH1/IDH2 and TP53 sections. If you are unsure, keep the report’s wording and ask your team to clarify it rather than selecting a different result. |
| You are newly diagnosed or looking after relapse. | Read Trials by Treatment Setting. Newly diagnosed and relapsed/refractory studies can have different entry requirements. Age limits and treatment fitness also need separate checks. |
| You are in remission or have a transplant history. | Review Maintenance / Post-Remission and Transplant Optimization. Check when enrollment occurs and which previous treatments the study permits or requires. |
Before checking a study, have these details ready:
- Your molecular report, including the exact result and test date.
- Your current disease setting and the names and dates of medicines, prior menin-inhibitor treatment if any, and any transplant.
- Your preferred study countries or locations and any practical travel limits.
Looking for a recruiting study? Open the linked registry record and check the recruitment label, relevant cohort and listed study sites. Then contact the study team about current local enrollment. A study marked recruiting overall may not have an open place at your preferred site.
You can begin a search with the information you know and leave uncertain molecular or treatment details as unknown. The study team must confirm eligibility and availability.
Selected Trials by Molecular Subtype
NPM1-Mutated / KMT2A-Rearranged — Menin Inhibitors
A major investigational drug class in AML. Menin inhibitors disrupt the menin–KMT2A interaction needed for HOX/MEIS1 gene activation in NPM1-mutated and KMT2A-rearranged leukemias. The Phase 3 combinations below mainly study newly diagnosed disease; they are not interchangeable with approved relapsed/refractory monotherapy indications:
- NCT07211958 — Revumenib plus intensive chemotherapy in newly diagnosed, untreated NPM1-mutated AML in candidates for intensive therapy (Registry: Phase 3; recruiting; age 12 Years to no stated upper limit. Other criteria apply.)
- NCT06652438 — Revumenib plus azacitidine/venetoclax for newly diagnosed NPM1-mutated or KMT2A-rearranged AML in adults ineligible for intensive induction; KMT2A partial tandem duplications/deletions are excluded (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT07007312 — Ziftomenib combinations for untreated AML: the non-intensive venetoclax/azacitidine study requires NPM1 mutation; the intensive 7+3 study permits NPM1 mutation or qualifying KMT2A rearrangement with additional FLT3 restrictions (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT06852222 — Bleximenib plus venetoclax/azacitidine in untreated NPM1-mutated or KMT2A-rearranged AML in adults ineligible for intensive chemotherapy (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT07223814 — Bleximenib with induction/consolidation then maintenance in newly diagnosed NPM1-mutated or KMT2A-rearranged AML in adults eligible for intensive chemotherapy (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT04988555 - Horizen-1: enzomenib (DSP-5336), a menin inhibitor, in relapsed or refractory acute leukemia (Phase 1/2). Enzomenib received FDA Breakthrough Therapy Designation, announced in October 2026 for relapsed or refractory KMT2A-rearranged acute leukemia. (Registry: Phase 1/2; recruiting; age 12 Years to no stated upper limit. Other criteria apply.)
FLT3-Mutated and FLT3-ITD Negative
FLT3-ITD and FLT3-TKD mutations occur in ~30% of AML. Trials combine FLT3 inhibitors with venetoclax, optimize post-transplant maintenance, and (new in 2026) extend the class into FLT3-ITD negative AML:
- NCT04293562 - CPX-351 and/or Gilteritinib vs standard chemo in newly diagnosed AML ± FLT3 mutations (Phase 3) (Registry: Phase 3; recruiting; age 6 Months to 21 Years. Other criteria apply.)
- NCT05586074 - HEC73543 vs salvage chemo in relapsed/refractory FLT3-ITD AML (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT07463651 — Gilteritinib versus sorafenib maintenance after allo-HSCT for FLT3-ITD AML with qualifying pre-transplant MRD and post-transplant recovery criteria (Registry: Phase 3; recruiting; age 14 Years to 70 Years. Other criteria apply.)
- NCT07478991 - Azacitidine + venetoclax ± quizartinib in first-line older/unfit AML (Phase 3 — tests adding the FLT3 inhibitor to the HMA + venetoclax backbone) (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
IDH1/IDH2-Mutated
- NCT07075016 - Ivosidenib + Azacitidine ± Venetoclax in newly diagnosed IDH1-mutated AML ineligible for intensive chemo (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT06387069 — HMPL-306 for relapsed/refractory AML with IDH1 R132 or IDH2 R140/R172 mutations; cohorts differ (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT05907057 - Ivosidenib + Azacitidine in newly diagnosed IDH1m AML (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
TP53-Mutated
The highest unmet need in AML — TP53-mutated disease has extremely poor prognosis with current therapies. Multiple novel agents are in development including combinations with HMA + venetoclax backbones. Enter the exact TP53 variant, if known, together with treatment history. Some trials require a specific variant such as Y220C; generic TP53 positivity is insufficient, and matching does not confirm eligibility.
Trials by Treatment Setting
Newly Diagnosed — Intensive (Fit Patients)
- NCT07132684 — VA versus D/IA induction for newly diagnosed fit adults aged 55–75; relapsed/refractory AML excluded (Registry: Phase 3; recruiting; age 55 Years to 75 Years. Other criteria apply.)
- NCT04628026 - Induction and consolidation chemo with Venetoclax in newly diagnosed AML/MDS-EB-2 (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to 75 Years. Other criteria apply.)
- NCT05805098 - Venetoclax + Homoharringtonine + Cytarabine induction (Phase 2/3) (Registry: Phase 2/3; recruiting; age 18 Years to 60 Years. Other criteria apply.)
- NCT06810791 - HVA vs IA/DA or VA in high-risk AML (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT05939180 - VA vs DA for newly diagnosed high-risk AML (Phase 2/3) (Registry: Phase 2/3; recruiting; age 18 Years to 64 Years. Other criteria apply.)
- NCT02416388 - Daunorubicin vs high-dose Idarubicin, intermediate vs high-dose cytarabine (Phase 2/3) (Registry: Phase 2/3; recruiting; age 18 Years to 61 Years. Other criteria apply.)
- NCT04168502 - Gemtuzumab ozogamicin MRD-guided in favorable/intermediate risk AML (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to 60 Years. Other criteria apply.)
Newly Diagnosed — Ineligible for Intensive Therapy
- NCT07581002 — Pivekimab sunirine plus venetoclax/azacitidine for newly diagnosed, untreated CD123-positive AML in adults ineligible for intensive induction; not a maintenance study (Registry: Phase 2/3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT06389292 — Lisaftoclax plus azacitidine for newly diagnosed AML ineligible for standard chemotherapy; age-specific performance-status rules apply (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT04256317 - AZTOUND: ASTX030 (oral azacitidine) ± Venetoclax (Phase 2/3) (Registry: Phase 2/3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT06345365 - MA + AZA regimen for newly diagnosed AML (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to 75 Years. Other criteria apply.)
Relapsed / Refractory
- NCT06713837 - IMPACT-AML: Pragmatic clinical trial for R/R AML (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT06418776 - IMPACT-AML: Randomized pragmatic trial for R/R AML (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to no stated upper limit. Other criteria apply.)
- NCT06788756 - L-Annamycin + Cytarabine second-line remission induction (Phase 2/3) (Registry: Phase 2/3; recruiting; age 18 Years to 80 Years. Other criteria apply.)
- NCT05726110 - Selinexor + HAD or CAG in R/R AML (Phase 3) (Registry: Phase 3; unknown; age 18 Years to 60 Years. Other criteria apply.)
Additional selected molecular and maintenance studies
- NCT06744504 — Cytarabine induction dose comparison for untreated RUNX1::RUNX1T1 AML; age 14–60 and fitness/organ criteria apply (Phase 3; recruiting).
- NCT07539818 — Azacitidine/venetoclax versus azacitidine maintenance after induction/consolidation in first CR/CRi; eligibility text requires age 14 to under 75, qualifying cytarabine exposure and MRD criteria. Prior allogeneic transplant is excluded (Phase 3; recruiting).
Maintenance / Post-Remission
- NCT05404906 - Azacitidine + Venetoclax maintenance in younger adults with AML in first remission (Phase 2/3) (Registry: Phase 2/3; recruiting; age 18 Years to 64 Years. Other criteria apply.)
- NCT06972641 - Molecular genetics-guided maintenance after allo-HSCT (Phase 2/3) (Registry: Phase 2/3; recruiting; age 14 Years to 75 Years. Other criteria apply.)
- NCT06802718 - Interferon-alpha maintenance for favorable-risk AML (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to 70 Years. Other criteria apply.)
- NCT06990321 - Medium-dose cytarabine + Venetoclax consolidation in elderly intermediate/high-risk AML (Phase 3) (Registry: Phase 3; recruiting; age 60 Years to 75 Years. Other criteria apply.)
Transplant Optimization
- NCT04314219 - Post-transplant cyclophosphamide vs SOC GVHD prophylaxis (Phase 3) (Registry: Phase 3; recruiting; age 14 Years to 65 Years. Other criteria apply.)
- NCT05429632 - Mocravimod adjunctive and maintenance in AML patients undergoing allo-HCT (Phase 3) (Registry: Phase 3; recruiting; age 18 Years to 75 Years. Other criteria apply.)
- NCT04708054 - Venetoclax to improve outcomes of busulfan conditioning in high-risk AML/MDS (Phase 2/3) (Registry: Phase 2/3; recruiting; age 18 Years to 70 Years. Other criteria apply.)
- NCT07396480 - Fludarabine + Melphalan ± Venetoclax conditioning for allo-HCT in AML/MDS patients >50 years (Phase 3) (Registry: Phase 3; recruiting; age 50 Years to 75 Years. Other criteria apply.)
- NCT05991908 - Fludarabine + single vs dual alkylating agent conditioning in myeloid malignancies (Phase 3) (Registry: Phase 3; recruiting; age 16 Years to 55 Years. Other criteria apply.)
- NCT05477589 - SCRIPT-AML: Pediatric AML conditioning regimen study (Phase 3) (Registry: Phase 3; recruiting; age not specified to 18 Years. Other criteria apply.)
- NCT03793517 - Decitabine + mBU/CY for high-risk acute leukemia with MRD pre-HSCT (Phase 2/3) (Registry: Phase 2/3; unknown; age 18 Years to 55 Years. Other criteria apply.)
Novel Approaches
- Menin inhibitors: Revumenib, ziftomenib, bleximenib — targeted agents for selected molecular subtypes; revumenib and ziftomenib FDA-approved for relapsed/refractory NPM1-mutated AML (Oct/Nov 2025), all three in frontline Phase 3 in 2026
- Next-gen BCL-2 inhibitors: Lisaftoclax (APG-2575), sonrotoclax — designed to improve on venetoclax
- Dual IDH inhibitors: HMPL-306 targeting both IDH1 and IDH2 mutations with a single agent
- MRD-guided therapy: Multiple trials using measurable residual disease to guide maintenance and transplant decisions
- Oral azacitidine combinations: ASTX030 (cedazuridine + azacitidine) studied as an oral formulation; combination partners and administration vary
- Antibody-drug conjugates: NCT07255872 - BL-M11D1 (novel ADC) + cytarabine/daunorubicin or venetoclax-based induction in AML (Phase 2/3) (Registry: Phase 2/3; recruiting; age 18 Years to 75 Years. Other criteria apply.)
- Pediatric AML: NCT05183035 - Venetoclax in children with R/R AML; NCT05994690 - CHIP-AML22 master protocol
A November 17 condition search for recruiting interventional AML studies returned 529 records, including 51 with a Phase 3 component; broad search results include transplant, supportive care and other acute leukemia settings, not 529 suitable treatment choices. Registry review November 17: NCT05183035 and NCT06578247 are active, not recruiting; NCT03793517 and NCT05726110 have unknown recruitment status. Confirm availability with the site. Age ranges are registry limits, not permission to enroll.
Primary regulatory sources: FDA revumenib; FDA ziftomenib; FDA oral decitabine/cedazuridine plus venetoclax. Each trial link opens its registry record.
Frequently Asked Questions
How do I find AML clinical trials for my mutation?
Use the guided questionnaire or paste a clinical summary with the exact molecular report, newly diagnosed versus relapsed/refractory status, prior treatments, transplant history and age. Include NPM1, FLT3-ITD/TKD, IDH1/2, KMT2A, TP53 and cytogenetics when available. The treating team and trial site must confirm eligibility.
What AML trials are currently recruiting?
Research includes menin, FLT3, IDH and BCL-2 approaches, induction combinations, post-remission treatment and transplant strategies. Current registry status, molecular cohort, prior treatment, age and fitness all matter. The selected list includes historical or unconfirmed studies with explicit status labels; it is not an eligibility determination.
Are there menin inhibitor trials open for NPM1-mutated AML?
Yes. Selected revumenib, ziftomenib and bleximenib combinations study untreated disease, with different intensive and non-intensive cohorts. Some require NPM1 mutation, some allow qualifying KMT2A rearrangements, and additional FLT3 or prior-treatment restrictions can apply. Approved relapsed/refractory monotherapy indications are separate.
Find AML Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific mutations, risk group, and treatment history.
Find Matching Trials